Biotech Values

[TraderUsa]

3 fairly recent Biotech mergers

Amgen-BioVex $1B
$425MM in cash plus $575MM in payments for regulatory and sale milestones
1 drug in Phase 3 that was recruiting patients
1 drug under development in the UK
An operational manufacturing facility

Amgen-Micromet $1.16B in cash
1 drug under going multiple trials with no further progression than ongoing Phase 2s
Proprietary BiTE antibody technology for future research and potential milestone/royalty payments from licensing
Rights to one antibody in Phase 1
A site for R&D

Celgene-Avila $925MM
$350MM in cash plus $195MM for milestones of the drug's successful development and approval, plus $380MM for milestones from drugs developed and approved from the platform
1 drug in Phase 1
Proprietary Avilomics Platform for discovery and development

What does OncoSec have to offer:
NeoPulse:
Ready for market
CE Mark for Europe,
Patent for China for method of use and device.
ImmunoPulse:
Phase 2 Malignant Melanoma
Phase 2 Merkel Cell Carcinoma
Phase 2 Cutaneous T-cell Lymphoma
Producing outstanding data thus far, in fact leading the way with their results

Think for yourselves people and do not listen to those underselling this company. Just look at the facts. The potential ONCS has is phenomenal. Personally, I am holding onto every possible share I can acquire. Trading this stock is very risky as virtually every professional analyst has this stock with an undervalued rating right now. Many giving it a current value of $2.00-$2.50pps. With 10 upcoming catalysts and several upcoming events, ONCS is sitting on the platform ready to launch. When ONCS goes, it will GO!

SOURCE: http://finance.yahoo.com/mbview/threadview/;_ylt=Amv7TE0yjhxbEMRr2cAz9SveAohG;_ylu=X3oDMTB2Y252cDRkBHBvcwMxOQRzZWMDTWVkaWFNc2dCb2FyZHNYSFJVbHQ-;_ylg=X3oDMTBvaWppbXYzBGxhbmcDZW4tVVMEdGVzdANUZXN0X0FGQw--;_ylv=3?&bn=deaf8eed-7d4e-3e9e-8004-c66f510cb300&tid=1365384886725-a0390b7f-3634-4ffd-b530-522740419b25&tls=la%2Cd%2C0%2C3